Trials / Completed
CompletedNCT03979937
Development and Validation of a Simple Diagnostic Tool Predictive of the Aseptic Character of Joint Effusion
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 328 (actual)
- Sponsor
- Centre Hospitalier le Mans · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Development and validation of a simple diagnostic tool predictive of the aseptic character of joint effusion in the primary care setting.
Detailed description
In accordance with guidelines and because of the potential gravity that this situation could represent, any joint effusion must be considered as a septic arthritis until proven otherwise, thus justifying an arthrocentesis and an adequate treatment. Nevertheless, because of epidemiology in primary care, this pragmatic attitude is quite commonly obscured and practices vary according to the experience of the doctor and his personal habits. As a result, the arthrocentesis is not commonly performed and anti-inflammatory treatment, whether based on NSAIDs or corticosteroids, is even sometimes administered to the patient despite the contrary guidelines. Although usually effective, this attitude is however not without risks. In this context, it seems interesting to develop a simple, reproducible and applicable diagnostic tool in a primary care setting for predicting the risk of septic arthritis. This study is therefore aimed at the development and validation of a predictive score based on simple clinical and paraclinical data (such as the macroscopic appearance of the synovial fluid removed) in a patient with an effusion, whatever either the clinical presentation, whether isolated or integrated in a more complex clinical presentation, whether associated with locoregional inflammatory or general signs or not.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Arthrocentesis | Arthrocentesis to determine the nature of the effusion (septic or aseptic). |
Timeline
- Start date
- 2020-02-15
- Primary completion
- 2022-03-01
- Completion
- 2022-03-01
- First posted
- 2019-06-10
- Last updated
- 2022-03-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03979937. Inclusion in this directory is not an endorsement.